Indication:
For the treatment of schizophrenia.
• Adults
The efficacy of aripiprazole in the treatment of schizophrenia was established in short-term (4-week and 6-week) controlled trials of adult patients with schizophrenia. Physicians who choose aripiprazole for long-term treatment should periodically reassess the long-term usefulness of the drug for the individual patient.
• Adolescents
The efficacy of aripiprazole in the treatment of schizophrenia in adolescent patients (13–17 years of age) was established in a 6-week placebo-controlled trial. Physicians who choose aripiprazole for long-term treatment should periodically reassess the long-term usefulness of the drug for the individual patient.